Glycobiology Advance Access originally published online on October 30, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glycobiology, 2003, Vol. 13, No. 2 97-107
© 2003 Oxford University Press
Heparin sequencing
4 Drug Development Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
5 Medical Oncology Department, University of Manchester, Manchester M20 4BX, UK
Received on May 24, 2002; revised on August 14, 2002; accepted on August 21, 2002
Heparin is a highly sulfated glycosaminoglycan widely used as an anticoagulant. Modifications in its relatively uniform structure appear to be key to its recognition and modulation of serine proteases, growth factors, chemokines, and extracellular proteins, as has been most clearly demonstrated in the antithrombin binding site. We sequenced the major oligosaccharides released from mastocytoma heparin by partial nitrous acid using a highly sensitive technique tailored for sequencing of metabolically radiolabeled heparin. It utilizes partial nitrous acid cleavage to allow simultaneous sequencing of the internal components of the oligosaccharide under investigation by specific lysosomal exoenzymes. Sequencing revealed that although the majority of the heparin disaccharides are N-, 2-O-, and 6-O-sulfated, the less sulfated disaccharides (lacking 2-O- or 6-O-sulfates) seem to be spaced out along the chain. The technique may be particularly useful for characterizing heparin from novel sources, such as the glial progenitor cells and Ascidia, as well as for sequencing protein binding sites.
2 Present address: Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA
3 Present address: Department of Chemistry and Biological Sciences, University of Huddersfield, UK
1 To whom correspondence should be addressed; e-mail: sallyelizabethstringer{at}yahoo.co.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Tissot, N. Gasiunas, A. K Powell, Y. Ahmed, Z.-l. Zhi, S. M Haslam, H. R Morris, J. E Turnbull, J. T Gallagher, and A. Dell Towards GAG glycomics: Analysis of highly sulfated heparins by MALDI-TOF mass spectrometry Glycobiology, September 1, 2007; 17(9): 972 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mahalingam, J. T. Gallagher, and J. R. Couchman Cellular Adhesion Responses to the Heparin-binding (HepII) Domain of Fibronectin Require Heparan Sulfate with Specific Properties J. Biol. Chem., February 2, 2007; 282(5): 3221 - 3230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. L. Wu and M. Lech Characterizing the Non-reducing End Structure of Heparan Sulfate J. Biol. Chem., October 7, 2005; 280(40): 33749 - 33755. [Abstract] [Full Text] [PDF]
|
|